Correlating cerebrospinal fluid (CSF) nAChR-related proteins (e.g., lynx1 or SLURP-1) with PD progression in ongoing nicotine trials could bridge this knowledge gap. The gene discussed is LYNX1; the disease is Parkinson disease.